Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1
Background: Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown.
Methods: NEAT001/ANRS143 is a randomized trial that showed noninferiority over 96 weeks of ritonavir-boosted darunavir plus raltegravir versus tenofovir disoproxil fumarate/emtricitabine in 805 antiretroviral antiretrovrial-naive HIV-infected adults. We compared changes in whole-blood telomere length measured with quantitative polymerase chain reaction in 201 randomly selected participants (104 raltegravir and 97 tenofovir disoproxil fumarate/emtricitabine). We performed multivariable estimative and predictive linear regression.
Results: At week 96, participants receiving tenofovir disoproxil fumarate/emtricitabine had a statistically significant higher gain in telomere length than participants receiving raltegravir. Difference in mean telomere length change between groups (tenofovir disoproxil fumarate/emtricitabine minus raltegravir) from baseline to week 96 adjusted by baseline telomere length was 0.031 (P = .009). This difference was not significantly confounded by age, gender, known duration of HIV infection, CD4 (baseline/nadir), CD8 cells, CD4/CD8 ratio, HIV viral load (baseline/week 96), tobacco and alcohol consumption, statins, or hepatitis C.
Conclusion: Antiretroviral-naive HIV-infected adults receiving ritonavir-boosted darunavir and tenofovir disoproxil fumarate/emtricitabine had a significant higher gain in blood telomere length than those receiving ritonavir-boosted darunavir and raltegravir, suggesting a better initial recovery from HIV-associated immunosenescence.
| Errataetall: |
CommentIn: J Infect Dis. 2018 Oct 5;218(10):1521-1522. - PMID 29912474 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:218 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 218(2018), 10 vom: 05. Okt., Seite 1523-1530 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stella-Ascariz, Natalia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
43Y000U234 |
|---|
| Anmerkungen: |
Date Completed 16.09.2019 Date Revised 16.09.2019 published: Print CommentIn: J Infect Dis. 2018 Oct 5;218(10):1521-1522. - PMID 29912474 Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiy399 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM286252317 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM286252317 | ||
| 003 | DE-627 | ||
| 005 | 20231225051251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiy399 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0954.xml |
| 035 | |a (DE-627)NLM286252317 | ||
| 035 | |a (NLM)29982509 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stella-Ascariz, Natalia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1 |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.09.2019 | ||
| 500 | |a Date Revised 16.09.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Infect Dis. 2018 Oct 5;218(10):1521-1522. - PMID 29912474 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown | ||
| 520 | |a Methods: NEAT001/ANRS143 is a randomized trial that showed noninferiority over 96 weeks of ritonavir-boosted darunavir plus raltegravir versus tenofovir disoproxil fumarate/emtricitabine in 805 antiretroviral antiretrovrial-naive HIV-infected adults. We compared changes in whole-blood telomere length measured with quantitative polymerase chain reaction in 201 randomly selected participants (104 raltegravir and 97 tenofovir disoproxil fumarate/emtricitabine). We performed multivariable estimative and predictive linear regression | ||
| 520 | |a Results: At week 96, participants receiving tenofovir disoproxil fumarate/emtricitabine had a statistically significant higher gain in telomere length than participants receiving raltegravir. Difference in mean telomere length change between groups (tenofovir disoproxil fumarate/emtricitabine minus raltegravir) from baseline to week 96 adjusted by baseline telomere length was 0.031 (P = .009). This difference was not significantly confounded by age, gender, known duration of HIV infection, CD4 (baseline/nadir), CD8 cells, CD4/CD8 ratio, HIV viral load (baseline/week 96), tobacco and alcohol consumption, statins, or hepatitis C | ||
| 520 | |a Conclusion: Antiretroviral-naive HIV-infected adults receiving ritonavir-boosted darunavir and tenofovir disoproxil fumarate/emtricitabine had a significant higher gain in blood telomere length than those receiving ritonavir-boosted darunavir and raltegravir, suggesting a better initial recovery from HIV-associated immunosenescence | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Raltegravir Potassium |2 NLM | |
| 650 | 7 | |a 43Y000U234 |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Emtricitabine |2 NLM | |
| 650 | 7 | |a G70B4ETF4S |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Darunavir |2 NLM | |
| 650 | 7 | |a YO603Y8113 |2 NLM | |
| 700 | 1 | |a Montejano, Rocio |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Centeno, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Alejos, Belen |e verfasserin |4 aut | |
| 700 | 1 | |a Schwimmer, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardino, Jose I |e verfasserin |4 aut | |
| 700 | 1 | |a Rodes, Berta |e verfasserin |4 aut | |
| 700 | 1 | |a Allavena, Clotilde |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffmann, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Gisslén, Magnus |e verfasserin |4 aut | |
| 700 | 1 | |a de Miguel, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban-Cantos, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Wallet, Cédrick |e verfasserin |4 aut | |
| 700 | 1 | |a Raffi, François |e verfasserin |4 aut | |
| 700 | 1 | |a Arribas, Jose R |e verfasserin |4 aut | |
| 700 | 0 | |a NEAT 001/ ANRS 143 Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 218(2018), 10 vom: 05. Okt., Seite 1523-1530 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:218 |g year:2018 |g number:10 |g day:05 |g month:10 |g pages:1523-1530 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiy399 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 218 |j 2018 |e 10 |b 05 |c 10 |h 1523-1530 | ||